Literature DB >> 24990142

Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.

Gautam Borthakur1, Jorge E Cortes, Elihu E Estey, Elias Jabbour, Stefan Faderl, Susan O'Brien, Guillermo Garcia-Manero, Tapan Mahendra Kadia, Xuemei Wang, Keyur Patel, Rajyalakshmi Luthra, Charles Koller, Mark Brandt, Farhad Ravandi, Hagop Kantarjian.   

Abstract

Despite being considered "good-risk" acute myelogenous leukemia (AML), long term outcomes in core binding factor (CBF) AML suggest room for improvement. We report on a regimen consisting of fludarabine, cytarabine, granulocyte colony stimulating factor, and low dose gemtuzumab ozogamicin (FLAG-GO) as front-line therapy of patients with CBF AML. Forty-five patients were enrolled (median age 48 years). Remission rate was 95% with 5% induction deaths. The overall survival (OS) and relapse free survival (RFS) probability at 3 years are 78% and 85%, respectively. FLAG-GO regimen results in high rates of RFS and OS in CBF AML. Our data along with recent data from several large groups strongly argues in favor of incorporation of gemtuzumab ozogamicin in frontline regimens for CBF AML.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24990142      PMCID： PMC4431614          DOI： 10.1002/ajh.23795

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


  26 in total

1.  Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type.

Authors:  Weina Chen; Dan Jones; L Jeffrey Medeiros; Rajyalashmi Luthra; Pei Lin
Journal:  Br J Haematol       Date:  2005-09       Impact factor: 6.998

2.  Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.

Authors:  Guido Marcucci; Krzysztof Mrózek; Amy S Ruppert; Kati Maharry; Jonathan E Kolitz; Joseph O Moore; Robert J Mayer; Mark J Pettenati; Bayard L Powell; Colin G Edwards; Lisa J Sterling; James W Vardiman; Charles A Schiffer; Andrew J Carroll; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

3.  Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.

Authors:  B F Goemans; C M Zwaan; M Miller; M Zimmermann; A Harlow; S Meshinchi; A H Loonen; K Hählen; D Reinhardt; U Creutzig; G J L Kaspers; M C Heinrich
Journal:  Leukemia       Date:  2005-09       Impact factor: 11.528

4.  Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered.

Authors:  J C Byrd; R K Dodge; A Carroll; M R Baer; C Edwards; J Stamberg; M Qumsiyeh; J O Moore; R J Mayer; F Davey; C A Schiffer; C D Bloomfield
Journal:  J Clin Oncol       Date:  1999-12       Impact factor: 44.544

5.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

Review 6.  Biochemical modulation of arabinosylcytosine for therapy of leukemias.

Authors:  V Gandhi; E Estey; M J Keating; W Plunkett
Journal:  Leuk Lymphoma       Date:  1993

7.  Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).

Authors:  R A Larson; M Boogaerts; E Estey; C Karanes; E A Stadtmauer; E L Sievers; P Mineur; J M Bennett; M S Berger; C B Eten; M Munteanu; M R Loken; J J M Van Dongen; I D Bernstein; F R Appelbaum
Journal:  Leukemia       Date:  2002-09       Impact factor: 11.528

8.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Authors:  Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

9.  Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.

Authors:  V Gandhi; E Estey; M J Keating; W Plunkett
Journal:  J Clin Oncol       Date:  1993-01       Impact factor: 44.544

10.  Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.

Authors:  John C Byrd; Amy S Ruppert; Krzysztof Mrózek; Andrew J Carroll; Colin G Edwards; Diane C Arthur; Mark J Pettenati; Judith Stamberg; Prasad R K Koduru; Joseph O Moore; Robert J Mayer; Frederick R Davey; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544
View more
  18 in total

Review 1.  Frontline treatment of acute myeloid leukemia in adults.

Authors:  Gevorg Tamamyan; Tapan Kadia; Farhad Ravandi; Gautam Borthakur; Jorge Cortes; Elias Jabbour; Naval Daver; Maro Ohanian; Hagop Kantarjian; Marina Konopleva
Journal:  Crit Rev Oncol Hematol       Date:  2016-12-11       Impact factor: 6.312

2.  Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia.

Authors:  Brittany Knick Ragon; Naval Daver; Guillermo Garcia-Manero; Farhad Ravandi; Jorge Cortes; Tapan Kadia; Betul Oran; Maro Ohanian; Alessandra Ferrajoli; Naveen Pemmaraju; Hagop M Kantarjian; Gautam Borthakur
Journal:  Am J Hematol       Date:  2017-06-09       Impact factor: 10.047

Review 3.  Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia.

Authors:  Patrick K Reville; Tapan Kadia
Journal:  Curr Treat Options Oncol       Date:  2020-04-21

4.  G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.

Authors:  Pamela S Becker; Bruno C Medeiros; Anthony S Stein; Megan Othus; Frederick R Appelbaum; Stephen J Forman; Bart L Scott; Paul C Hendrie; Kelda M Gardner; John M Pagel; Roland B Walter; Cynthia Parks; Brent L Wood; Janis L Abkowitz; Elihu H Estey
Journal:  Am J Hematol       Date:  2015-01-30       Impact factor: 10.047

Review 5.  The cure of leukemia through the optimist's prism.

Authors:  Hagop M Kantarjian; Nitin Jain; Guillermo Garcia-Manero; Mary Alma Welch; Farhad Ravandi; William G Wierda; Elias J Jabbour
Journal:  Cancer       Date:  2021-10-06       Impact factor: 6.860

Review 6.  Clinical implications of molecular markers in acute myeloid leukemia.

Authors:  Sabine Kayser; Mark J Levis
Journal:  Eur J Haematol       Date:  2018-10-23       Impact factor: 2.997

Review 7.  Emerging therapies for inv(16) AML.

Authors:  Sridevi Surapally; Daniel G Tenen; John A Pulikkan
Journal:  Blood       Date:  2021-05-13       Impact factor: 22.113

Review 8.  New Treatment Options for Older Patients with Acute Myeloid Leukemia.

Authors:  Kapil Saxena; Marina Konopleva
Journal:  Curr Treat Options Oncol       Date:  2021-03-20

9.  Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801.

Authors:  Guido Marcucci; Susan Geyer; Kristina Laumann; Weiqiang Zhao; Donna Bucci; Geoffrey L Uy; William Blum; Ann-Kathrin Eisfeld; Timothy S Pardee; Eunice S Wang; Wendy Stock; Jonathan E Kolitz; Jessica Kohlschmidt; Krzysztof Mrózek; Clara D Bloomfield; Richard M Stone; Richard A Larson
Journal:  Blood Adv       Date:  2020-02-25

Review 10.  Core binding factor acute myelogenous leukemia-2021 treatment algorithm.

Authors:  Gautam Borthakur; Hagop Kantarjian
Journal:  Blood Cancer J       Date:  2021-06-16       Impact factor: 11.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.